[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630336":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":23,"locations":23,"responsibleParty":27,"collaborators":23,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":23,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":23,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":54,"whyStopped":23,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":23},{"fullName":5,"class":6},"Marmara University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Shoulder PENG Block","ACTIVE_COMPARATOR","Procedure: Ultrasound-guided shoulder pericapsular nerve group block Drug: 15 mL of 0.25% bupivacaine (37.5 mg)",[13],"Other: shoulder pericapsular nerve group block",{"label":15,"type":10,"description":16,"interventionNames":17},"Interscalene Block (ISB)","Procedure: Ultrasound-guided conventional intrafascial interscalene block at C5-C6 level Drug: 15 mL of 0.25% bupivacaine (37.5 mg)",[18],"Other: Interscalene Nerve Block",[20,24],{"type":6,"name":21,"description":16,"armGroupLabels":22,"otherNames":23},"Interscalene Nerve Block",[15],null,{"type":6,"name":25,"description":11,"armGroupLabels":26,"otherNames":23},"shoulder pericapsular nerve group block",[9],{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Beliz Bilgili","Prof Dr","100630336","shoulder-pericapsular-block-versus-interscalene-block-in-arthroscopic-shoulder-surgery-100630336",false,"NCT07486349","Shoulder Pericapsular Block Versus Interscalene Block in Arthroscopic Shoulder Surgery","Ultrasound-Guided Interscalene Block Versus Shoulder Pericapsular Nerve Group (PENG) Block for Hemidiaphragmatic Paralysis in Elective Shoulder Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA physical status I-III\n* Scheduled for elective shoulder surgery under general anesthesia\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pre-existing diaphragmatic dysfunction\n* Severe COPD or restrictive pulmonary disease\n* Neuromuscular disorders\n* BMI \\> 40 kg\u002Fm²\n* Coagulopathy\n* Infection at injection site\n* Allergy to local anesthetics\n* Inability to undergo diaphragmatic ultrasound assessment","ALL","18 Years","75 Years",{"count":42,"type":43},70,"ESTIMATED","INTERVENTIONAL",[46],"NA","This randomized controlled trial aims to compare the incidence of hemidiaphragmatic paralysis (HDP) following ultrasound-guided interscalene block (ISB) versus shoulder pericapsular nerve group (PENG) block in patients undergoing elective shoulder surgery under general anesthesia.\n\nThe primary objective is to determine whether the shoulder PENG block reduces the incidence of HDP compared with conventional intrafascial ISB. HDP will be assessed using ultrasound measurement of diaphragmatic excursion 30 minutes after block performance",[49],"Hemidiaphragmatic Paralysis",[51,52,53],"hemidiaphragmatic paralysis","intescalen block","shoulder pericapsular nerve group","NOT_YET_RECRUITING","2026-03-18",{"date":57,"type":58},"2026-03-20","ACTUAL",{"date":60,"type":43},"2026-04-01",{"date":62,"type":43},"2026-12-01",{"name":5,"class":6}]